The most common gastrointestinal alterations in patients with post-COVID syndrome
INTRODUCTION: Post-COVID syndrome may affect the gastrointestinal tract. However, risk factors of post-COVID syndrome are still unknown.
OBJECTIVE: We aimed to identify the most common gastrointestinal symptoms, abnormal laboratory findings and risk factors relevant to post-COVID syndrome.
METHOD: In this retrospective study, we included 79 patients admitted to Semmelweis University Department of Surgery, Transplantation and Gastroenterology between October 2020 and September 2022. We investigated clinical data, laboratory findings and determined the major risk factors.
RESULTS: Most of the patients were women (46/79), their mean age was 47.6 years and patients were overweight (BMI: 26.3 kg/m2). The most common comorbidities were cardiovascular diseases (21/79), hypertension (20/79), diabetes (11/79) and malignant diseases (9/79). Typical indications for gastroscopy were dyspepsia (16/79) and epigastric pain (10/79). The most common indications for colonoscopy were diarrhea (29/79) and weight loss (28/79). Among abnormal laboratory findings, liver enzymes levels (GOT: 83.5 U/L, GPT: 85 U/L, GGT: 70 U/L) and ferritin (351.5 ng/mL) were higher in post-COVID patients. Typical conditions diagnosed by gastroscopy, colonoscopy and abdominal ultrasound were gastroesophageal reflux disease (11/26), irritable bowel syndrome (2/19) and diffuse hepatic lesions, respectively. The number of unvaccinated patients was higher compared to those receiving any COVID-19 vaccines (58% vs. 29%). Of the vaccinated patients, 12 patients received mRNA vaccines (10 Pfizer-BioNTech, 2 Moderna) and 6 patients received viral vector vaccines (2 AstraZeneca, 4 Sputnik V).
CONCLUSION: We identified female gender, obesity, cardiovascular diseases, cancer, hypertension and diabetes as major risk factors of post-COVID syndrome. Vaccinated status may prevent post-COVID gastrointestinal symptoms. Orv Hetil. 2023; 164(31): 1206-1212.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:164 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 164(2023), 31 vom: 06. Aug., Seite 1206-1212 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A poszt-COVID-szindrómával diagnosztizált betegek leggyakoribb gastrointestinalis eltérései |
|---|
| Beteiligte Personen: |
Angyal, Kata [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID–19 vaccines |
|---|
| Anmerkungen: |
Date Completed 08.08.2023 Date Revised 08.08.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2023.32839 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360436501 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360436501 | ||
| 003 | DE-627 | ||
| 005 | 20231226083017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2023.32839 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360436501 | ||
| 035 | |a (NLM)37543972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Angyal, Kata |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The most common gastrointestinal alterations in patients with post-COVID syndrome |
| 246 | 3 | 3 | |a A poszt-COVID-szindrómával diagnosztizált betegek leggyakoribb gastrointestinalis eltérései |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.08.2023 | ||
| 500 | |a Date Revised 08.08.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Post-COVID syndrome may affect the gastrointestinal tract. However, risk factors of post-COVID syndrome are still unknown | ||
| 520 | |a OBJECTIVE: We aimed to identify the most common gastrointestinal symptoms, abnormal laboratory findings and risk factors relevant to post-COVID syndrome | ||
| 520 | |a METHOD: In this retrospective study, we included 79 patients admitted to Semmelweis University Department of Surgery, Transplantation and Gastroenterology between October 2020 and September 2022. We investigated clinical data, laboratory findings and determined the major risk factors | ||
| 520 | |a RESULTS: Most of the patients were women (46/79), their mean age was 47.6 years and patients were overweight (BMI: 26.3 kg/m2). The most common comorbidities were cardiovascular diseases (21/79), hypertension (20/79), diabetes (11/79) and malignant diseases (9/79). Typical indications for gastroscopy were dyspepsia (16/79) and epigastric pain (10/79). The most common indications for colonoscopy were diarrhea (29/79) and weight loss (28/79). Among abnormal laboratory findings, liver enzymes levels (GOT: 83.5 U/L, GPT: 85 U/L, GGT: 70 U/L) and ferritin (351.5 ng/mL) were higher in post-COVID patients. Typical conditions diagnosed by gastroscopy, colonoscopy and abdominal ultrasound were gastroesophageal reflux disease (11/26), irritable bowel syndrome (2/19) and diffuse hepatic lesions, respectively. The number of unvaccinated patients was higher compared to those receiving any COVID-19 vaccines (58% vs. 29%). Of the vaccinated patients, 12 patients received mRNA vaccines (10 Pfizer-BioNTech, 2 Moderna) and 6 patients received viral vector vaccines (2 AstraZeneca, 4 Sputnik V) | ||
| 520 | |a CONCLUSION: We identified female gender, obesity, cardiovascular diseases, cancer, hypertension and diabetes as major risk factors of post-COVID syndrome. Vaccinated status may prevent post-COVID gastrointestinal symptoms. Orv Hetil. 2023; 164(31): 1206-1212 | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID–19 vaccines | |
| 650 | 4 | |a COVID–19-oltások | |
| 650 | 4 | |a gastrointestinal symptoms | |
| 650 | 4 | |a gastrointestinalis tünetek | |
| 650 | 4 | |a post-COVID syndrome | |
| 650 | 4 | |a poszt-COVID-szindróma | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Tajthy, Anna Mandula |e verfasserin |4 aut | |
| 700 | 1 | |a Drácz, Bálint |e verfasserin |4 aut | |
| 700 | 1 | |a Miheller, Pál |e verfasserin |4 aut | |
| 700 | 1 | |a Horváth, Miklós |e verfasserin |4 aut | |
| 700 | 1 | |a Székely, Hajnal |e verfasserin |4 aut | |
| 700 | 1 | |a Papp, Veronika |e verfasserin |4 aut | |
| 700 | 1 | |a Czompa, Diána |e verfasserin |4 aut | |
| 700 | 1 | |a Szijártó, Attila |e verfasserin |4 aut | |
| 700 | 1 | |a Werling, Klára |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 164(2023), 31 vom: 06. Aug., Seite 1206-1212 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:164 |g year:2023 |g number:31 |g day:06 |g month:08 |g pages:1206-1212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2023.32839 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2023 |e 31 |b 06 |c 08 |h 1206-1212 | ||